Why Is Bio-Path (BPTH) Stock Up 89% Today?

Bio-Path (NASDAQ:BPTH) stock is rising higher on Thursday after the oncology company announced an update on its Phase 1/1b clinical trial of BP1002.This clinical trial is focusing on the use of BP1002 as a treatment for refractory/relapsed acute myeloid leukemia (AML). It’s focusing on patients with AML and patients who are venetoclax resistant.Bio-Path is currently testing the dose escalation portion of its Phase 1/1b study. The company notes that it has successfully completed its second dose cohort in thi ...